e-drug
[Top] [All Lists]

[e-drug] Indian drug R&D has bright future

E-DRUG: Indian drug R&D has bright future
-----------------------------------------

LONDON: A few years ago, Western drug makers would never have dreamt of putting 
their research dollars to work in India, a country associated with pirating 
medicines invented elsewhere. 

Today, pharmaceutical executives are predicting a surge of investment to 
exploit a low-cost base of scientific talent. 

India is coming in from the cold with the adoption of patent protection for 
medicines from next year, removing a key obstacle to investment that will help 
skew future R&D efforts firmly towards Asia. 

Research by FT Corporate Solutions and law firm Linklaters, presented at a 
conference this week, found 82 per cent of senior executives and analysts 
expected a rise in Asian R&D investment over the next decade, with India 
leading the way. 

The United States remains top of pile, tipped by 75 per cent of respondents as 
the leading region in the hunt for new medicines. But 14 per cent backed Asia 
as the dominant force within 10 years, ahead of Europe with just eight per 
cent. 

Brian Tempest, chief executive of India's biggest pharmaceutical company, 
Ranbaxy Laboratories, is not surprised. He believes the $400 billion-a-year 
global drugs business is finally waking up to India's potential. 

"There are lots of cost efficiencies in India... We vary between one-fifth and 
one-seventh of the costs in America," he told Reuters. 

In some areas the advantage is even bigger. Pfizer, for example, calculates 
that it costs $800 a month to employ a chemist in India against $12,000 in the 
United States. 

At a time when big pharmaceutical companies face "a classic margin squeeze" 
from rising costs and low prices, according to a recent comment by AstraZeneca 
chief executive Tom McKillop, the incentive to outsource to India is growing. 
 
Research alliances 

A year ago, GlaxoSmithKline struck a research collaboration deal with Ranbaxy 
designed to tap into India's considerable chemistry skills in the search for 
innovative medicines. 
It is business model more Western firms are expected to follow. 

"There are other companies that want to do similar deals with us but we don't 
want to let that take too big a percentage of our drug discovery activity," 
Tempest said. 

For Ranbaxy and rivals such as Dr Reddy's Laboratories, which has done deals 
with both Novo Nordisk and Novartis AG, it is all part of a strategy to move up 
the value chain. 
Indian firms are, simultaneously, moving fast to internationalise their generic 
drugs business. 

In 2000, the United States accounted for just 14 per cent of Ranbaxy sales. 
Last year it had reached 43 per cent and by 2007 Ranbaxy wants the US to make 
up half of group sales, which are tipped by then to have doubled to $2 billion. 

India may not have much time to make its transition to higher-value 
pharmaceutical programmes before China emerges as a new, powerful competitive 
force. 

"We have a window of six or seven years. Ranbaxy is going to jump through it 
and become stronger  but then we will have to deal with the Chinese," Tempest 
said. 

China is currently strong in producing pharmaceutical ingredients but is not a 
major supplier to world markets of finished products. 

And research investment in the country has been held in check by concerns about 
China's poor reputation for defending intellectual property rights, as 
highlighted by this year's decision to overturn Pfizer's patent on 
anti-impotence drug Viagra. 



<Prev in Thread] Current Thread [Next in Thread>